Fundz

Nanoscope Therapeutics, Inc. reported raising $12.8 Million in an initial SEC Form D filing, from an offering of $16.1 Million

PRIVATEJul 22, 2020$12.8M of $16.1M raised

Amount Raised

$12.8 Million

$12.8 Million sold, per SEC Form D (first sale Jul 22, 2020)

Round Type

Venture

DallasBiotechnologyHealth CareMedicalTherapeutics

Quick answer

Nanoscope Therapeutics raised $12.8 Million in a funding round, dated July 22, 2020. Nanoscope Therapeutics is based in Dallas, Texas, United States.

How much did Nanoscope Therapeutics raise?
Nanoscope Therapeutics raised $12.8 Million in a funding round on July 22, 2020.
What does Nanoscope Therapeutics do?
Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists.
Where is Nanoscope Therapeutics based and how big is it?
Nanoscope Therapeutics is based in Dallas, Texas, United States. Fundz records about 43 employees.
Who are the decision-makers at Nanoscope Therapeutics?
Fundz holds 2 contacts at Nanoscope Therapeutics. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Medical and Therapeutics around the same time

Companies in the same sectors as Nanoscope Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Kinnate Biopharma raised $88M on August 4, 2020.
  • Immunome Inc. raised $11M on June 16, 2020.
  • Escient Pharmaceuticals raised $33M on September 4, 2020.
  • Monteris Medical raised $9M on September 4, 2020.
  • ORTHALIGN INC raised $11M on September 2, 2020.
  • Adipo Therapeutics raised $1.3M (Seed) on September 2, 2020.

Who to call at Nanoscope Therapeutics, and when

A new round usually means Nanoscope Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Nanoscope Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Nanoscope Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Nanoscope Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Nanoscope Therapeutics

Location

1312 BROWN TRAIL

Dallas, Texas, United States

About

Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in H1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial, also in the first half of 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Nanoscope Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Predictive Intelligence
Strategic

ML-powered predictions for Nanoscope Therapeutics's next move

See what Strategic adds

Nanoscope Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.